Skip to content
DataLookout
Menu

NCT07894341

A Clinical Study of Long-Term Administration of Inpegsomatropin Injection in Participants With Idiopathic Short Stature Who Have Completed Phase Ⅲ Clinical Trials

StatusRecruiting
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Safety: number of participants with adverse event (AE), serious adverse events (SAE) and clinically significant examination results.
Timeframe: Every 13 weeks during the first year, and then every 52 weeks (up to 16 years)

Secondary (6)

Change in height standard deviation score (ΔHT-SDS)
Height velocity (HV)
Change in height velocity (ΔHV)
Change in insulin-like growth factor-1 standard deviation score (ΔIGF-1-SDS)
Ratio of change in bone age to change in chronological age (ΔBA/ΔCA)
Show 1 moreShow less
Final height (FH)

Arms and interventions

Inpegsomatropin-Injection GroupExperimental

Drugs: Inpegsomatropin Injection

Sites

27 sites in 1 country